Search results for "ARTERIAL"

showing 10 items of 714 documents

Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease R…

2017

Introduction: There is a growing interest in nutraceuticals improving cardiovascular risk factor levels and related organ damage. Methods: This double-blind, placebo-controlled randomized clinical trial aims to compare the effect of a combined nutraceutical containing red yeast rice (10 mg), phytosterols (800 mg), and l-tyrosol (5 mg) on lipid profile, blood pressure, endothelial function, and arterial stiffness in a group of 60 patients with polygenic hypercholesterolemia resistant to Mediterranean diet. Results: After 8 weeks of treatment, when compared to the placebo group, the active treated patients experienced a more favorable percentage change in total cholesterol (−16.3% vs 9.9…

MaleBlood Pressure030204 cardiovascular system & hematologyGastroenterologychemistry.chemical_compoundDietary supplement0302 clinical medicineRisk FactorsPhytosterolPharmacology (medical)030212 general & internal medicineEndothelial dysfunctionOriginal ResearchFramingham Risk Scoremedicine.diagnostic_testAnticholesteremic AgentsFatty liverPhytosterolsGeneral MedicineMiddle AgedDietary supplementsCholesterolBiochemistryCardiovascular DiseasesFemaleNutraceuticalsNutraceuticalAdultmedicine.medical_specialtyl-TyrosolHypercholesterolemiaPlacebo03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansRisk factorBiological ProductsCholesterolbusiness.industryHemodynamicsmedicine.diseaseCardiovascular disease riskBlood pressurechemistryRed yeast riceArterial stiffnessLipid profilebusinessBiomarkers
researchProduct

Prevalence and Risk Factors of PAD among Patients with Elevated ABI

2008

ObjectivesTo assess the prevalence and clinical significance of elevated ankle-brachial index (ABI) in patients referred to vascular consultation.DesignRetrospective clinical study.Material and methodsIn 1,762 patients referred with a suspicion of peripheral arterial disease (PAD), ABI and toe brachial index (TBI) were measured by photoplethysmography. ABI≥1.3 was considered falsely elevated and TBI<0.60 was the diagnostic criterion for PAD.ResultsThe prevalence of elevated ABI was 8.4% and that of PAD among these patients 62.2%. PAD was significantly more prevalent among subjects with severe symptoms (rest pain, ulcers or gangrene) than in those with intermittent claudication (83.8% and 45…

MaleBrachial ArteryArterial diseaseBlood PressureCoronary DiseaseIschemiaRisk FactorsOdds RatioPrevalenceMedicineMediasclerosisReferral and ConsultationFinlandAged 80 and overPeripheral Vascular DiseasesGangreneMedicine(all)SmokingMiddle AgedPeripheralFemalemedicine.symptomCardiology and Cardiovascular Medicinemedicine.medical_specialtyOutpatient Clinics HospitalAnkle brachial pressure indexRisk AssessmentSensitivity and SpecificityAge DistributionPredictive Value of TestsInternal medicinePeripheral arterial diseaseHumansIn patientClinical significancecardiovascular diseasesPhotoplethysmographyAgedRetrospective Studiesbusiness.industryExtremitiesmedicine.diseaseIntermittent claudicationCoronary heart diseaseSurgerybody regionsToe Brachial IndexKidney Failure ChronicSurgeryAnklebusinessEuropean Journal of Vascular and Endovascular Surgery
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake &lt;48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience

2019

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Target therapy can cause various cardiovascular complications. The aim of this study was to evaluate the burden of cardiovascular complications related to treatment with anti-BCR-ABL tyrosine kinase inhibitors (TKIs) and to determine if there are differences between the latest- and first-generation TKIs. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A retrospective observational study was carried out on 55 patients (39 men, 16 women; mean age ± SD: 58 ± 11 years) treated with TKIs targeting Bcr-Abl for a median period of 3.5 years. Patients were divided in two groups according to the type of treatment. Group A included patients treated with…

MaleCancer Researchmedicine.medical_specialtyGastrointestinal Stromal TumorsDasatinibFusion Proteins bcr-ablCoronary Artery DiseasePulse Wave AnalysisCardio-oncology Cardiotoxicity Tyrosine kinase inhibitors Chronic myeloid leukemia Arterial stiffness03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveMedicineHumans030212 general & internal medicineAdverse effectPulse wave velocityProtein Kinase InhibitorsAgedGastrointestinal NeoplasmsRetrospective Studiesbusiness.industryPonatinibImidazolesRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseThrombosisrespiratory tract diseasesDasatinibPyridazinesPyrimidinesTreatment OutcomeOncologyNilotinibchemistry030220 oncology & carcinogenesisArterial stiffnessCardiologyImatinib MesylateFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome

2020

The aim of this study was to assess the value of echocardiographic right ventricular (RV) and systolic pulmonary artery pressure (sPAP) assessment in predicting transcatheter tricuspid edge-to-edge valve repair (TTVR) outcome.RV dysfunction and pulmonary hypertension are associated with poor prognosis and are systematically sought during tricuspid regurgitation evaluation. The value of echocardiographic assessment in predicting TTVR outcome is unknown.Data were taken from the TriValve (Transcatheter Tricuspid Valve Therapies) registry, which includes patients undergoing TTVR at 14 European and North American centers. The primary outcome was 1-year survival free from hospitalization for hear…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsRegurgitation (circulation)Pulmonary Artery030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicinePrimary outcomePredictive Value of TestsInternal medicinemedicine.arteryVentricular PressureHumansMedicineArterial PressureProspective StudiesRegistries030212 general & internal medicineAgedAged 80 and overHeart FailureHospital readmissionTricuspid valvebusiness.industryRecovery of FunctionMiddle Agedmedicine.diseasePulmonary hypertensionTricuspid Valve Insufficiency3. Good healthPulmonary pressureEuropeTreatment Outcomemedicine.anatomical_structureEchocardiographyHeart failureNorth AmericaPulmonary arteryDisease ProgressionVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Growth Differentiation Factor-15 (GDF-15) Levels Are Associated with Cardiac and Renal Injury in Patients Undergoing Coronary Artery Bypass Grafting …

2014

International audience; Objective: Growth differentiation factor-15 (GDF-15) has been identified as a strong marker of cardiovascular disease; however, no data are available concerning the role of GDF-15 in the occurrence of organ dysfunction during coronary artery bypass grafting (CABG) associated with cardiopulmonary bypass (CPB). Methods: Five arterial blood samples were taken sequentially in 34 patients from anesthesia induction (IND) until 24 h after arrival at the intensive care unit (ICU). Plasma levels of GDF-15, follistatin-like 1 (FLST1), myeloperoxidases (MPO), hydroperoxides and plasma antioxidant status (PAS) were measured at each time-point. Markers of cardiac (cardiac-troponi…

MaleCardiothoracic SurgeryCardiovascular ProceduresGeneral Anesthesialcsh:Medicine030204 cardiovascular system & hematologyAntioxidantslaw.inventionPostoperative Complications0302 clinical medicineAnesthesiologylawTroponin IMedicine and Health SciencesCoronary Heart DiseaseMedicineAnesthesiaCoronary Artery Bypasslcsh:Science0303 health sciencesCardiopulmonary BypassCoronary Artery Bypass GraftingMultidisciplinaryAcute kidney injuryAcute Kidney InjuryMiddle AgedLipocalins[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthCardiac surgeryIntensive Care UnitsCardiovascular Diseasesembryonic structuresCardiologyArterial bloodFemalemedicine.symptomResearch Articlemedicine.medical_specialtyFollistatin-Related ProteinsGrowth Differentiation Factor 15Heart DiseasesCardiac SurgeryCardiologyRenal functionSurgical and Invasive Medical Procedures03 medical and health sciencesLipocalin-2[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPredictive Value of TestsProto-Oncogene ProteinsInternal medicineCardiopulmonary bypassHumansAgedPeroxidase030304 developmental biologybusiness.industryTroponin Ilcsh:ROrgan dysfunctionHydrogen Peroxidemedicine.diseaseSurgerylcsh:QGDF15businessBiomarkersAcute-Phase Proteins
researchProduct

Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma

2017

Objective To determine if perfusion in surgical cavity wall enhancement (SCWE) obtained in early post-treatment MR imaging can stratify time-to-progression (TTP) in glioblastoma. Materials and methods This study enrolled 60 glioblastoma patients with more than 5-mm-thick SCWEs as detected on contrast-enhanced MR imaging after concurrent chemoradiation therapy. Two independent readers categorized the shape and perfusion state of SCWEs as nodular or non-nodular and as having positive or negative perfusion compared with the contralateral grey matter on arterial spin labeling (ASL). The perfusion fraction on ASL within the contrast-enhancing lesion was calculated. The independent predictability…

MaleCentral Nervous Systemlcsh:MedicineContrast MediaKaplan-Meier EstimatePathology and Laboratory MedicineNervous SystemDiagnostic Radiology030218 nuclear medicine & medical imaging0302 clinical medicineFunctional Magnetic Resonance ImagingMedicine and Health SciencesBlastomasMedicinelcsh:ScienceNeurological TumorsBrain MappingMultidisciplinarymedicine.diagnostic_testBrain NeoplasmsRadiology and ImagingChemoradiotherapyCombined Modality TherapyMagnetic Resonance ImagingDacarbazinePerfusionmedicine.anatomical_structureOncologyNeurology030220 oncology & carcinogenesisDisease ProgressionFemaleAnatomymedicine.symptomPerfusionResearch Articlemedicine.drugImaging TechniquesSurgical and Invasive Medical ProceduresNeuroimagingGrey matterResearch and Analysis MethodsLesion03 medical and health sciencesSigns and SymptomsText miningDiagnostic MedicineArterial Spin LabellingImage Interpretation Computer-AssistedTemozolomideHumansAgedTemozolomideSurgical Resectionbusiness.industryProportional hazards modellcsh:RCancers and NeoplasmsBiology and Life SciencesMagnetic resonance imagingmedicine.diseaseLesionslcsh:QSpin LabelsGlioblastomabusinessNuclear medicineGlioblastoma MultiformeNeuroscienceGlioblastomaPLOS ONE
researchProduct

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy

2020

Background Few data are available on the rate and characteristics of thromboembolic complications in hospitalized patients with COVID-19. Methods We studied consecutive symptomatic patients with laboratory-proven COVID-19 admitted to a university hospital in Milan, Italy (13.02.2020–10.04.2020). The primary outcome was any thromboembolic complication, including venous thromboembolism (VTE), ischemic stroke, and acute coronary syndrome (ACS)/myocardial infarction (MI). Secondary outcome was overt disseminated intravascular coagulation (DIC). Results We included 388 patients (median age 66 years, 68% men, 16% requiring intensive care [ICU]). Thromboprophylaxis was used in 100% of ICU patients…

MaleComorbidity030204 cardiovascular system & hematologyBrain Ischemia0302 clinical medicineHospitals UrbanPatient AdmissionRisk FactorsPulmonary angiographyAmbulatory CareThrombophiliaCardiovascular complicationsMyocardial infarctionHospital MortalityAged 80 and overHematologyMiddle AgedPulmonary embolismItaly030220 oncology & carcinogenesisAmbulatoryFemaleCoronavirus InfectionsVenous thromboembolismmedicine.medical_specialtyAcute coronary syndromeCritical CarePneumonia ViralArterial Occlusive DiseasesDisseminated intravascular coagulationThrombophiliaArticle03 medical and health sciencesInternal medicineIntensive caremedicineHumansAcute Coronary SyndromeMortalityHospitals TeachingPandemicsAgedRetrospective Studiesbusiness.industryCoronary ThrombosisAnticoagulantsCOVID-19Retrospective cohort studyLength of Staymedicine.diseaseSARS-CoV2businessPulmonary EmbolismThrombosis Research
researchProduct

Early albumin infusion improves global and local hemodynamics and reduces inflammatory response in hemorrhagic shock.

2002

Objective To evaluate the effects of an early, short-term albumin infusion on mesenteric microcirculation and global hemodynamics in hemorrhagic shock. Design A prospective, randomized study. Setting Animal laboratory at a university medical clinic. Subjects Seventeen Sprague-Dawley rats weighing 250–400 g. Interventions The rats underwent median laparotomy and exteriorization of an ileal loop for intravital microscopy of the mesenteric microcirculation. Volume-controlled hemorrhagic shock was provoked by arterial blood withdrawal (2.5 mL/100 g body weight for 60 mins), followed by a 4-hr reperfusion period. Albumin (20%) or 0.9% NaCl was administered intravenously as a continuous infusion …

MaleHemodynamicsHematocritShock HemorrhagicCritical Care and Intensive Care MedicineMicrocirculationRats Sprague-DawleyRandom AllocationIntensive careAlbuminsmedicineAnimalsMesenteryProspective StudiesInfusions Intravenousmedicine.diagnostic_testbusiness.industryMicrocirculationCentral venous pressureHemodynamicsBlood flowRatsAnesthesiaShock (circulatory)Arterial bloodmedicine.symptomBlood Gas AnalysisbusinessCritical care medicine
researchProduct

Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.

2020

International audience; Hepatocellular carcinoma is the fourth leading cause of cancer death. For unresectable intermediate-stage hepatocellular carcinoma, the standard treatment is transarterial chemoembolization. To date, the overall survival at three years remains low, and there is currently no consensus about the best anticancer agent and optimal treatment regimen. We report the case of a hepatocellular carcinoma patient with a vascular contraindication to embolization who achieved a complete response after four intra-arterial infusions of idarubicin emulsified with lipiodol. The patient maintained his response over a three-year period without any hepatocellular carcinoma treatment, dem…

MaleHepatocellular carcinoma[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterologyEthiodized Oil0302 clinical medicineMESH: Infusions Intra-ArterialMESH: Liver NeoplasmsPharmacology (medical)EmbolizationMESH: Carcinoma HepatocellularComplete responseMESH: Treatment OutcomeMESH: AgedStandard treatmentLiver Neoplasms[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodol030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyIntra-arterial therapyCarcinoma HepatocellularAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesMESH: Ethiodized OilInternal medicinemedicineHumansInfusions Intra-ArterialIdarubicinContraindicationAgedMESH: Humansbusiness.industryMESH: Idarubicinmedicine.diseasedigestive system diseasesMESH: MaleRegimenMESH: Antineoplastic AgentsbusinessIdarubicin
researchProduct